Long-term stability of bone mineral density in kidney transplant recipients treated with low-dose steroids and cyclosporine: Protective effect of cyclosporine?;STABILITE A LONG TERME DE LA DENSITE MINERALE OSSEUSE DES TRANSPLANTES RENAUX SOUS CICLOSPORINE ET FAIBLES DOSES DE CORTICOIDES: ROLE PROTECTEUR DE LA CICLOSPORINE?

Presse Medicale

Volumn 27, Issue 15, 1998, Pages 705-712

  Ezaitouni, F ^a   Westeel, P F ^a   Fardellone, P ^a   Mazouz, H ^a   Brazier, M ^a   El Esper, I ^a   Sebert, J L ^a   Petit, J ^a   Westeel, A ^a   Pruna, A ^a   Fournier, A ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ALUMINUM; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; STEROID; CORTICOSTEROID;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CANCELLOUS BONE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; DRUG EFFECT; FEMUR NECK; GRAFT REJECTION; HORMONE DETERMINATION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; OSTEOPENIA; PARATHYROID FUNCTION; PARATHYROID GLAND; RADIUS; TRABECULAR BONE; DOSE RESPONSE; REVIEW;

ADRENAL CORTEX HORMONES; BONE DENSITY; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KIDNEY TRANSPLANTATION;

EID: 0032542871     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bonomini RW, Feletti C, Di Felice A, Buscaroli A. Bone remodelling after renal transplantation. In: Phosphate and Mineral Metabolism, Massry SG ed. Plenum Press 1984:207-16.
2. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991 ; 325:544-50.
3. Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P. Changes in Bone Mass early after kidney transplantation. J Bone Miner Res 1994 ; 9:1-9.
4. Pichette V, Bonnardeaux A, Prudhomme L, Gagné M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectionaland longitudinal study. Am J Kidney Dis 1996 ; 28:105-114.
5. Grotz WH, Mundinger FA, Rasenack J et al. Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrol Dial Transplant 1995 ; 10:2096-100.
6. McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant 1995 ; 9:20-4.
7. Briner VA, Landmann J, Brunner FP, Thiel G. Cyclosporin A-induced transient rise in plasma alkaline phosphatase in kidney transplant patients. Transpl Int 1993 ; 6:99-107.
8. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporine A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988 ; 123:2571-7.
9. Movsowitz C, Epstein S, Ismail F. Cyclosporine A in oophrectomized rat: unexpected severe bone resorption. J Bone Miner Res 1989 ; 4:393-8.
10. Epstein S. Post-transplantation bone desease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 1996 ; 11:1-7.
11. Thiebaud D, Krieg MA, Gillart-Berguer D, Jacquet AF, Goy JJ, Burckhardt P. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Euro J Clin Invest 1996 ; 26:549-55.
12. Delmas PD, Schlemmer A, Flineyts E, Rüs B, Christiansen C. Urinary excretion of pyridinoline cross links correlates with bone turn over measured on iliac crest biopsy in patents with vertebral osteoperosis. J Bone Miner Res 1991 ; 6:639-44.
13. Kamel S, Brazier M, Desmet G, Picard C, Mennecier I, Sebert JL. High performance liquid chromatographic of 3 hydroxypyridinium derivates as new markers of bone resorption. J Chromatogr 1992 ; 574:255-60.
14. Brown RC, Aston JP, Weeks I, Woohead S. Circulating intact PTH measured by a two site immunochemiluminometric assay. J Clin Endocr Metab 1997 ; 65:407-14.
15. Grant RA. Estimation of hydroxyproline by autoanalyzer. J Clin Pathol 1964 ; 17:685-6.
16. Hill CS, Wolfert RC. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chem Acta 1989 ; 186:315-19.
17. Farrugia W, Melick RA. Metabolism of osteocalcine. Calcif Tissue Int 1986 ; 39:234-8.
18. Malluche HH, Faugere MC, Fanti P, Price PA. Plasma levels of bone Gla-Protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 1984 ; 26:869-74.
19. Kelly TL. Bone mineral density reference database for american men and women. J Bone Miner Res 1990 ; 5:S249.
20. Gluer CC, Reiser UJ, Davis CA, Rutt BK, Genant HK. Vertébral mineral determination by quantitative computed tomography (QCT): accuracy of single and dual energy measurements. J Comput Assist Tomogr 1988 ; 12:242-59.
21. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis : pathogenesis and management. Ann Intern Med 1990 ; 112:352-64.
22. Piraino B, Chen T, Cooperstin L, Segre GV, Puschett S Fractures and vertebral bone mineral density in patents with renal osteo dystrophy. Clin Nephrol 1988 ; 30:57-62.
23. Kleevekoper M, Nelson DA Which bone density measurement? J Bone Miner Res 1997 ; 12:712-14.
24. Massary PV. Disorders of bone and mineral metabolism after transplantation. Kidney Int 1997 ; 52:1412-21.
25. Reinhardt W, Bartel Worth H, Jackenhövel F et al. Sequential changes of biochemical bone parameters after kidney. Nephrol Dial Transplant 1998 ; 13:436-42.
26. Reeve J. PTH a future role in the management of osteoporosis. J Bone Am Res 1996 ; 11:440-5.
27. Torres A, Machado M, Conception MT et al. Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kidney Int 1996 ; 50:1726-33.
28. Boiskin I, Epstein S, Ismail F, Thomas B, Raja R. Serum osteocalcin and bone mineral metabolism following successful renal transplantation. Clin Nephrol 1989 ; 31:316-22.
29. Cosman F, Nieves J, Herbert J, Shein V, Lindsay R. High-Dose Glucocorticoids in Multiple Sclerosis Patients Exert Direct Effetcs on the Kidney and Skeleton. J Bone Miner Res 1994 ; 9:1097-105.
30. LoCascio V, Bonucci E, Imbimbo B et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990 ; 8:39-51.
31. Morrison N, Eisman J. Role of the neagtive glucocorticoid regulatory element in glucocorticoid repression ot the human osteocalcin promoter. Bone Miner Res 1993 ; 8:969-75.
32. Gray RES, Doherty SM, Galloway J, Coulton L, de Broe M, Kanis JA. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum 1990 ; 34:287-95.
33. Bourbigot B, Moal MC, Cledes J. Bone histology in renal transplant patients receiving cyclosporin. Lancet 1988 ; i:1049.
34. Stewart PJ, Green OC, Stern PH. Cyclosporine a inhibits calcemic hormone-induced bone resorption in vitro. Bone Miner Res 1986 ; 1:285-91.
35. Stewart PJ, Stern PH. Cyclosporine: correlation of immunosuppresive activity and inhibition of bone resorption. Calcif Tissue Int 1989 ; 45:222-6.
36. Orcel P, Denne MA, De Vernejoul MC. Cyclosoporin A in vitro decreases bone resorption, osteoclast formation and fusion of cells of the monocyte-macrophage lineage. Endocrinology 1991 ; 128:1638-46.
37. Chowdhury MM, Shen V, Dempsier DU. Effects of cyclosporine A on Chuck osteodasts in vitro. Calcif Tissue Int 1991 ; 49:275-9.
38. Muraoka D, Fujimoto K, Sun Y, Yoshioka K, Yamamoto K Immunosuppressant FK 506 induces interleukin 6 production through the activation of transcription of a nuclear factor NF-KB. J Clin Invest 1996 ; 97:2433-9.
39. Orcel P, Bielakoff J, Modrowski D, Miravet L, De Vernejoul MC. Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone. J J Bone Miner Res 1989 ; 4:387-91.
40. Movsowitz C, Schlosberg M, Epstein S, Ismail F, Fallon M, Thomas S. Combined treatment with cyclosporin A and cortisone acetate minimized the adverse bone effects of either agent alone. J Orthop Res 1990 ; 8:635-41.
41. Parry RG, Jackson J, Stevens JM, Higgins B, Altmann P. Long term bone densitometry post renal transplantation in patients treated with celler cyclosporin or prednisolone. Nephrol Dial Transplant 1998 ; 13:531-2.